Heteromerization of chemokine (C-X-C motif) receptor 4 with α1A/B -adrenergic receptors controls adrenergic α1 receptor function

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 13, 2015, Pages E1659-E1668

  Tripathi, Abhishek ^a   Vana, P Geoff ^a   Chavan, Tanmay S ^b   Brueggemann, Lioubov I ^a   Byron, Kenneth L ^a   Tarasova, Nadya I ^c   Volkman, Brian F ^d   Gaponenko, Vadim ^b   Majetschak, Matthias ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

AMD3100; Blood pressure; CXCL12; Phenylephrine; Ubiquitin

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CALCIUM ION; CHEMOKINE RECEPTOR CXCR4; DOPAMINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; MYOSIN LIGHT CHAIN 2; PHENYLEPHRINE; PLERIXAFOR; UBIQUITIN; ADRA1A PROTEIN, HUMAN; ADRA1A PROTEIN, RAT; ADRA1B PROTEIN, HUMAN; ADRA1B PROTEIN, RAT; CXCL12 PROTEIN, HUMAN; CXCL12 PROTEIN, RAT; CXCR4 PROTEIN, HUMAN; CXCR4 PROTEIN, RAT; HETEROCYCLIC COMPOUND; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CALCIUM MOBILIZATION; CELL SURFACE; CLINICAL EVALUATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DIMERIZATION; EC50; GENE EXPRESSION SYSTEM; GENE SILENCING; GENETIC ASSOCIATION; HELA CELL LINE; HETEROMERIZATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN TARGETING; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; ANIMAL; BLOOD PRESSURE; CELL MEMBRANE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; LEWIS RAT; MALE; METABOLISM; PROTEIN MOTIF; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT;

RATTUS;

AMINO ACID MOTIFS; ANIMALS; BLOOD PRESSURE; CELL MEMBRANE; CHEMOKINE CXCL12; DIMERIZATION; HELA CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHENYLEPHRINE; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, CXCR4; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84961289810     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1417564112     Document Type: Article

References (78)

1. Regard JB, Sato IT, Coughlin SR (2008) Anatomical profiling of G protein-coupled receptor expression. Cell 135(3):561-571.
2. Bachelerie F, et al. (2014) International Union of Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev 66(1):1-79.
3. Teicher BA, Fricker SP (2010) CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16(11):2927-2931.
4. Nagasawa T, Tachibana K, Kishimoto T (1998) A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: Their functions in development, hematopoiesis and HIV infection. Semin Immunol 10(3):179-185.
5. Chu PY, et al. (2011) CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess. Circ Heart Fail 4(5):651-658.
6. Yu L, Hales CA (2011) Effect of chemokine receptor CXCR4 on hypoxia-induced pulmonary hypertension and vascular remodeling in rats. Respir Res 12:21.
7. Bach HH, IV, et al. (2012) Initial assessment of the role of CXC chemokine receptor 4 after polytrauma. Mol Med 18:1056-1066.
8. Bach HH, IV, et al. (2014) Chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3 regulate vascular α?-adrenergic receptor function. Mol Med 20:435-447.
9. Earle SA, Proctor KG, Patel MB, Majetschak M (2005) Ubiquitin reduces fluid shifts after traumatic brain injury. Surgery 138(3):431-438.
10. Majetschak M, et al. (2004) Effects of exogenous ubiquitin in lethal endotoxemia. Surgery 135(5):536-543.
11. Majetschak M, Cohn SM, Obertacke U, Proctor KG (2004) Therapeutic potential of exogenous ubiquitin during resuscitation from severe trauma. J Trauma 56(5): 991-999; discussion 999-1000.
12. Baker TA, et al. (2012) Effects of exogenous ubiquitin in a polytrauma model with blunt chest trauma. Crit Care Med 40(8):2376-2384.
13. Moore CA, Milano SK, Benovic JL (2007) Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol 69:451-482.
14. Busillo JM, Benovic JL (2007) Regulation of CXCR4 signaling. Biochim Biophys Acta 1768(4):952-963.
15. Marchese A, Chen C, Kim YM, Benovic JL (2003) The ins and outs of G protein-coupled receptor trafficking. Trends Biochem Sci 28(7):369-376.
16. Rockman HA, Koch WJ, Lefkowitz RJ (2002) Seven-transmembrane-spanning receptors and heart function. Nature 415(6868):206-212.
17. Diviani D, et al. (1996) Effect of different G protein-coupled receptor kinases on phosphorylation and desensitization of the alpha1B-adrenergic receptor. J Biol Chem 271(9):5049-5058.
18. Collins S, et al. (1990) Mechanisms involved in adrenergic receptor desensitization. Biochem Soc Trans 18(4):541-544.
19. McGraw DW, et al. (2006) Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex. J Clin Invest 116(5):1400-1409.
20. Dzimiri N (2002) Receptor crosstalk. Implications for cardiovascular function, disease and therapy. Eur J Biochem 269(19):4713-4730.
21. Rozenfeld R, Devi LA (2010) Receptor heteromerization and drug discovery. Trends Pharmacol Sci 31(3):124-130.
22. Ferré S, et al. (2014) G protein-coupled receptor oligomerization revisited: Functional and pharmacological perspectives. Pharmacol Rev 66(2):413-434.
23. Milligan G, Canals M, Pediani JD, Ellis J, Lopez-Gimenez JF (2006) The role of GPCR dimerisation/oligomerisation in receptor signalling. Ernst Schering Found Symp Proc (2):145-161.
24. Rodríguez-Frade JM, et al. (2004) Blocking HIV-1 infection via CCR5 and CXCR4 receptors by acting in trans on the CCR2 chemokine receptor. EMBO J 23(1):66-76.
25. Watts AO, et al. (2013) Identification and profiling of CXCR3-CXCR4 chemokine receptor heteromer complexes. Br J Pharmacol 168(7):1662-1674.
26. Contento RL, et al. (2008) CXCR4-CCR5: A couple modulating T cell functions. Proc Natl Acad Sci USA 105(29):10101-10106.
27. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B (2009) CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 113(24):6085-6093.
28. Stanasila L, Perez JB, Vogel H, Cotecchia S (2003) Oligomerization of the alpha 1a- and alpha 1b-adrenergic receptor subtypes. Potential implications in receptor internalization. J Biol Chem 278(41):40239-40251.
29. Small KM, et al. (2006) Alpha2A- and alpha2C-adrenergic receptors form homo- and heterodimers: The heterodimeric state impairs agonist-promoted GRK phosphorylation and beta-arrestin recruitment. Biochemistry 45(15):4760-4767.
30. Barki-Harrington L, Luttrell LM, Rockman HA (2003) Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: A functional role for re-ceptor-receptor interaction in vivo. Circulation 108(13):1611-1618.
31. Lavoie C, et al. (2002) Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J Biol Chem 277(38):35402-35410.
32. Xu J, et al. (2003) Heterodimerization of alpha 2A- and beta 1-adrenergic receptors. J Biol Chem 278(12):10770-10777.
33. Prinster SC, Holmqvist TG, Hall RA (2006) Alpha2C-adrenergic receptors exhibit enhanced surface expression and signaling upon association with beta2-adrenergic receptors. J Pharmacol Exp Ther 318(3):974-981.
34. Chandrasekera PC, Wan TC, Gizewski ET, Auchampach JA, Lasley RD (2013) Adenosine A1 receptors heterodimerize with β1- and β2-adrenergic receptors creating novel receptor complexes with altered G protein coupling and signaling. Cell Signal 25(4): 736-742.
35. Mustafa S, et al. (2012) Identification and profiling of novel α1A-adrenoceptor-CXC chemokine receptor 2 heteromer. J Biol Chem 287(16):12952-12965.
36. LaRocca TJ, et al. (2010) β2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J Cardiovasc Pharmacol 56(5):548-559.
37. Nakai A, Hayano Y, Furuta F, Noda M, Suzuki K (2014) Control of lymphocyte egress from lymph nodes through β2-adrenergic receptors. J Exp Med 211(13):2583-2598.
38. Söderberg O, et al. (2006) Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 3(12):995-1000.
39. Brueggemann LI, et al. (2014) Differential protein kinase C-dependent modulation of Kv7.4 and Kv7.5 subunits of vascular Kv7 channels. J Biol Chem 289(4):2099-2111.
40. Tripathi A, Davis JD, Staren DM, Volkman BF, Majetschak M (2014) CXC chemokine receptor 4 signaling upon co-activation with stromal cell-derived factor-1α and ubiquitin. Cytokine 65(2):121-125.
41. Hebert TE, et al. (1996) A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 271(27):16384-16392.
42. Tarasov SG, et al. (2011) Structural plasticity of a transmembrane peptide allows selfassembly into biologically active nanoparticles. Proc Natl Acad Sci USA 108(24): 9798-9803.
43. Satoh M, Enomoto K, Takayanagi I, Koike K (1999) Analysis of alpha1-adrenoceptor subtypes in rabbit aorta and arteries: Regional difference and co-existence. Eur J Pharmacol 374(2):229-240.
44. Bokoch MP, et al. (2010) Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 463(7277):108-112.
45. Wu B, et al. (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330(6007):1066-1071.
46. Manglik A, et al. (2012) Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature 485(7398):321-326.
47. Wu H, et al. (2012) Structure of the human ê-opioid receptor in complex with JDTic. Nature 485(7398):327-332.
48. Salom D, et al. (2006) Crystal structure of a photoactivated deprotonated intermediate of rhodopsin. Proc Natl Acad Sci USA 103(44):16123-16128.
49. Huang J, Chen S, Zhang JJ,Huang XY(2013) Crystal structure of oligomeric β1-adrenergic G protein-coupled receptors in ligand-free basal state. Nat Struct Mol Biol 20(4):419-425.
50. Saini V, Marchese A, Majetschak M (2010) CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. J Biol Chem 285(20):15566-15576.
51. Saini V, et al. (2011) The CXC chemokine receptor 4 ligands ubiquitin and stromal cellderived factor-1α function through distinct receptor interactions. J Biol Chem 286(38): 33466-33477.
52. Soto AG, Trejo J (2010) N-linked glycosylation of protease-activated receptor-1 second extracellular loop: A critical determinant for ligand-induced receptor activation and internalization. J Biol Chem 285(24):18781-18793.
53. Lapham CK, et al. (2002) CXCR4 heterogeneity in primary cells: Possible role of ubiquitination. J Leukoc Biol 72(6):1206-1214.
54. Carlisle AJ, Lyttle CA, Carlisle RY, Maris JM (2009) CXCR4 expression heterogeneity in neuroblastoma cells due to ligand-independent regulation. Mol Cancer 8:126.
55. Grochmal A, Ferrero E, Milanesi L, Tomas S (2013) Modulation of in-membrane receptor clustering upon binding of multivalent ligands. J Am Chem Soc 135(27): 10172-10177.
56. Gnus J, et al. (2012) In vitro study on the effects of some selected agonists and antagonists of alpha(1)-adrenergic receptors on the contractility of the aneurysmallychanged aortic smooth muscle in humans. J Physiol Pharmacol 63(1):29-34.
57. Kern A, Albarran-Zeckler R, Walsh HE, Smith RG (2012) Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism. Neuron 73(2):317-332.
58. Yan L, Cai Q, Xu Y (2013) The ubiquitin-CXCR4 axis plays an important role in acute lung infection-enhanced lung tumor metastasis. Clin Cancer Res 19(17):4706-4716.
59. Muppidi A, et al. (2014) Targeted delivery of ubiquitin-conjugated BH3 peptide-based Mcl-1 inhibitors into cancer cells. Bioconjug Chem 25(2):424-432.
60. Steagall RJ, et al. (2014) Extracellular ubiquitin increases expression of angiogenic molecules and stimulates angiogenesis in cardiac microvascular endothelial cells. Microcirculation 21(4):324-332.
61. Tan C, Lu X, Chen W, Chen S (2014) Serum ubiquitin via CXC chemokine receptor 4triggered cyclooxygenase-1 ubiquitination possibly involved in the pathogenesis of aspirin resistance. Clin Hemorheol Microcirc, 10.3233/CH-141900.
62. Cao Y, Li C, Zhang Q, Wang Y, Xia R (2014) Extracellular ubiquitin enhances the suppressive effects of regulatory T cells on effector T cell responses. Clin Lab 60(12): 1983-1991.
63. Balabanian K, et al. (2005) The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 280(42):35760-35766.
64. Boudot A, et al. (2011) Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells. PLoS ONE 6(6):e20898.
65. Kieffer AE, et al. (2003) The N- and C-terminal fragments of ubiquitin are important for the antimicrobial activities. FASEB J 17(6):776-778.
66. Goupil E, et al. (2015) Angiotensin II type I and prostaglandin F2alpha receptors cooperatively modulate signaling in vascular smooth muscle cells. J Biol Chem 290(5): 3137-3148.
67. Milligan G, Smith NJ (2007) Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends Pharmacol Sci 28(12):615-620.
68. Ferré S, et al. (2009) Building a new conceptual framework for receptor heteromers. Nat Chem Biol 5(3):131-134.
69. Malik R, Soh UJ, Trejo J, Marchese A (2012) Novel roles for the E3 ubiquitin ligase atrophin-interacting protein 4 and signal transduction adaptor molecule 1 in G proteincoupled receptor signaling. J Biol Chem 287(12):9013-9027.
70. Brueggemann LI, Mackie AR, Mani BK, Cribbs LL, Byron KL (2009) Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Mol Pharmacol 76(5):1053-1061.
71. Henderson KK, Byron KL (2007) Vasopressin-induced vasoconstriction: Two concen-tration-dependent signaling pathways. J Appl Physiol (1985) 102(4):1402-1409.
72. Mackie AR, et al. (2008) Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance. J Pharmacol Exp Ther 325(2):475-483.
73. Veldkamp CT, Seibert C, Peterson FC, Sakmar TP, Volkman BF (2006) Recognition of a CXCR4 sulfotyrosine by the chemokine stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12). J Mol Biol 359(5):1400-1409.
74. Abraham SJ, Kobayashi T, Solaro RJ, Gaponenko V (2009) Differences in lysine pKa values may be used to improve NMR signal dispersion in reductively methylated proteins. J Biomol NMR 43(4):239-246.
75. Malik R, Marchese A (2010) Arrestin-2 interacts with the endosomal sorting complex required for transport machinery to modulate endosomal sorting of CXCR4. Mol Biol Cell 21(14):2529-2541.
76. O'Connor C, et al. (2010) p62/sequestosome-1 associates with and sustains the expression of retroviral restriction factor TRIM5alpha. J Virol 84(12):5997-6006.
77. Eiraku M, et al. (2011) Self-organizing optic-cup morphogenesis in three-dimensional culture. Nature 472(7341):51-56.
78. Tripathi A, et al. (2013) Modulation of the CXC chemokine receptor 4 agonist activity of ubiquitin through C-terminal protein modification. Biochemistry 52(24): 4184-4192.